Rasburicase

Therapeutic indications

Rasburicase is indicated for:

Acute hyperuricaemia in haematological malignancy

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Rasburicase is contraindicated in the following cases:

G6PD deficiency, cellular metabolic disorders causing haemolytic anaemia

at least one of
Glucose-6-phosphate dehydrogenase deficiency anemia
Anemia due to extrinsic red cell abnormality
Anemia due to enzyme deficiency
Anemia due to membrane defect
Hemolytic anemia due to hexokinase deficiency

Haemolytic anaemia

Hemolytic anemia

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: FASTURTEC Powder and solvent for concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈